eligibility_summary
Inclusion: consent, age 18–75, survival >12 wks, MM per IMWG with measurable disease (by M‑protein, sFLC for light‑chain, or extramedullary >1 cm). Phase I esc: ≥3 prior lines, prior BCMA, refractory, Phase I exp/Phase II: prior BCMA (bispecific/ADC/CAR‑T). Adequate organ function, contraception to 2 yrs. Exclusion: pregnancy/breastfeeding, HIV/active HBV/HCV, CNS involvement, significant autoimmune, uncontrolled infection, ASCT <8 wks or planned, prior allo‑SCT, bendamustine <1 yr, per PI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: OriCAR-017, an autologous anti‑GPRC5D chimeric antigen receptor T‑cell (CAR‑T) therapy (gene‑modified cellular immunotherapy). Mechanism of action: patient T cells are engineered to express a CAR that binds GPRC5D, triggering CAR signaling (CD3ζ with costimulatory domains), T‑cell activation, cytokine release, and cytolytic killing of target cells. Targets: GPRC5D, an orphan GPCR highly expressed on malignant plasma cells in multiple myeloma with limited normal tissue expression. Cells/pathways engaged: effector CD8+/CD4+ CAR‑T cells, antigen‑dependent cytotoxic/apoptotic pathways in GPRC5D+ myeloma cells, BCMA‑independent targeting suitable after prior BCMA‑directed therapies. Phase I/II, single‑arm study in relapsed/refractory MM.